Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

Description

This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).

Conditions

Major Depressive Episode, Borderline Personality Disorder, Suicide

Talk to us

Study Overview

On this page

Study Details

Study overview

This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).

Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

Condition
Major Depressive Episode
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02129

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18-65 years of age
  • * Diagnosed with BPD or MDE
  • * Chief complaint of suicidal thoughts and behaviors
  • * Neurological conditions with known structural brain lesion
  • * Prior neurosurgical procedure
  • * Metal in the body that is ferromagnetic or metal injury to the eyes
  • * Epilepsy
  • * Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt
  • * Psychopathology not appropriate for the treatment (e.g., manic episode or psychosis)
  • * Current alcohol dependence or active symptoms of non-alcohol psychoactive substance use withdrawal, as indicated by self-report
  • * Inability to meet the safety criteria for MRI scanning according to the protocols of the MGH Department of Radiology
  • * Current pregnancy

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Joan Camprodon, MD/PhD, PRINCIPAL_INVESTIGATOR, 6177265348

Study Record Dates

2025-02-28